A report on the work by BCM researchers with fibroblast growth factor receptor 1 appears today in the journal Cancer Cell.
“Since we are manipulating the target gene itself, we can ask, what will happen" If we turn it off, what happens" That recapitulates the effect of a specific drug,” said Dr. David Spencer, professor of immunology at BCM. “By turning the gene on and off at various time points, we can define a ‘susceptibility window’ for that drug, a time in the progression of the disease when the gene would be an appropriate target.”
That therapeutic “window” defines the time when shutting off the gene would also shut down progression of the cancer. Previous studies show that fibroblast growth factor receptor 1 may have a role in initiating prostate cancer, he said. As a result, some companies have developed drugs designed to block the receptor. Spencer’s work looks at what would happen if the receptor is blocked.
In his mouse, he used a synthetic drug that turned the re-engineered fibroblast growth factor receptor on. As the gene product was activated, the prostate gland began dramatic, synchronized changes characteristic of cancer. However, when he withdrew the drug that turned the receptor on, the changes reversed over several weeks until the prostate gland appeared normal.
However, at a certain point, changes in the tissue reach a point of no-return and transform in to a kind of cancer called adenocarcinoma that does not appear to be reversible, although withdrawing the drug can slow the cancer, too.
During this study, Spencer, his graduate student, Victor Acevedo and their colleagues also studied the changes prostate cells undergo while they spread outside the gland and into surrounding tissue. Understanding the events that take place in cells during the transition from normal to cancer can provide important clues about cancer and potential treatments.
From this study, he has identified some of the genes involved in the transition from normal prostate cells within a secretory gland to more migratory, malignant cells outside the gland. Using special gene chips called tumor microarrays, they have also discovered the up regulation or increase in cellular levels of Fzd4, a gene that might prove to be a new marker for human prostate cancer.
“Victor started out looking for a role of fibroblast growth factor receptor 1 in prostate cancer progression and ended up with a new cancer marker and a model for epithelial cell plasticity, rounding out his productive thesis,” Spencer added.
Novel mechanisms of action discovered for the skin cancer medication Imiquimod
21.10.2016 | Technische Universität München
Second research flight into zero gravity
21.10.2016 | Universität Zürich
Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.
"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...
In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.
A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...
By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.
"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...
COMPAMED has become the leading international marketplace for suppliers of medical manufacturing. The trade fair, which takes place every November and is co-located to MEDICA in Dusseldorf, has been steadily growing over the past years and shows that medical technology remains a rapidly growing market.
In 2016, the joint pavilion by the IVAM Microtechnology Network, the Product Market “High-tech for Medical Devices”, will be located in Hall 8a again and will...
'Ferroelectric' materials can switch between different states of electrical polarization in response to an external electric field. This flexibility means they show promise for many applications, for example in electronic devices and computer memory. Current ferroelectric materials are highly valued for their thermal and chemical stability and rapid electro-mechanical responses, but creating a material that is scalable down to the tiny sizes needed for technologies like silicon-based semiconductors (Si-based CMOS) has proven challenging.
Now, Hiroshi Funakubo and co-workers at the Tokyo Institute of Technology, in collaboration with researchers across Japan, have conducted experiments to...
14.10.2016 | Event News
14.10.2016 | Event News
12.10.2016 | Event News
21.10.2016 | Health and Medicine
21.10.2016 | Information Technology
21.10.2016 | Materials Sciences